The Linde Group has announced an agreement to install a CRYOHEAT system at SynTheAll Pharmaceuticals, a wholly owned subsidiary of WuXi PharmaTech in Shanghai.

CRYOHEAT is specifically designed to provide both the cooling and heating needs of process reaction vessels with a single unit, and will be supplied to WuXi PharmaTech, as a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the US.

The custom system is suitable for existing plant structures and for new builds. Under the terms of the contract, Linde will also supply engineering services, maintenance support and associated bulk gases.

“We envisage good global demand for our cryogenic technology. Our intimate knowledge of the industry, the ability of our engineers to understand key customer issues and Linde’s ability to provide custom solutions will drive future growth for us,” said Joe Eschbach, Head of Marketing Chemicals and Energy with the Gases Division of The Linde Group.

Dr Eric Gu, Vice President of Manufacturing of WuXi PharmaTech, added, “The installation of Linde’s CRYOHEAT, an important part of our expansion plan, greatly enhances our manufacturing service capability.”

“It enables us to deploy a complete turnkey solution from an advanced cryogenic system to gas and engineering services. Linde engineers also have excellent knowledge and a good understanding of our needs.”

Linde automated temperature control systems can significantly minimise maintenance and plant down time, while also offering increased accuracy in temperature control thereby improving efficiency, reducing energy consumption and preventing recurring operational issues such as ice formation. As a result, product yield and plant production capacity are greatly improved.